In the global intention-to-treat population, Pola-R-CHP showed significant progression-free survival benefit over R-CHOP ...

In a matched analysis involving 110 patients with transformed indolent non-Hodgkin lymphoma (TriNHL) and 391 patients with de ...

Acalabrutinib combined with lenalidomide and rituximab shows promising results as a frontline treatment for follicular lymphoma, achieving high response rates.

Rochester, N.Y. — A trailblazing new study suggests a new way to effectively treat certain types of cancer. Research conducted at the Wilmot Cancer Institute shows immunotherapy to be highly effective ...

Researchers assessed the safety and efficacy of combining glofitamab with R-CHOP or Pola-R-CHP among patients with high-risk LBCL aged 65 years or younger.

A treatment that rallies the immune system to destroy cancer raised the survival rate for advanced Hodgkin lymphoma patients to a remarkable 92 percent, suggesting a new standard therapy for the ...

The FDA has approved the combination of lurbinectedin (Zepzelca) and the immunotherapy atezolizumab (Tecentriq) for first-line maintenance treatment in patients with extensive-stage small cell lung ...

Learn the signs, symptoms, risk factors, and treatments for Hodgkin lymphoma—plus insights from a doctor who’s also a ...

ROCHESTER, N.Y. (WROC) — A groundbreaking Hodgkin lymphoma study from the University of Rochester Medical Center showed a 92% survival rate with fewer side effects and reduced radiation therapy use.

Stage 3 Hodgkin’s lymphoma either indicates lymphoma in the lymph nodes both above and below a person’s diaphragm or in the lymph nodes above the diaphragm and in the spleen. Doctors may also refer to ...